Items Tagged ‘General Bone Cancer’

August 6th, 2013

Xgeva Safe and Effective for Giant Cell Tumor of the Bone

By

The planned interim results of an international, open-label, phase 2 clinical trial published in the Lancet Oncology indicate that Xgeva® (denosumab) is safe and effective in the treatment of giant cell tumor of the bone. In fact, 96 percent of patients with surgically unsalvageable disease had no disease progression after a median follow-up of 13 […]

View full entry

Tags: Bone Cancer, General Bone Cancer, News


July 17th, 2013

Xgeva Approved for Treatment of Giant Cell Tumor of the Bone

By

The U.S. Food and Drug Administration (FDA) has expanded the approved use of Xgeva® (denosumab) to include the treatment of adults and some adolescents with giant cell tumor of the bone (GCTB). Giant cell tumor of bone (GCTB) is a rare, aggressive, benign osteolytic tumor in which bone destruction is mediated by a protein known […]

View full entry

Tags: Bone Cancer, General Bone Cancer, News


October 2nd, 2012

Xgeva Reduces Giant-cell Tumor of the Bone

By

Xgeva® (denosumab) significantly reduced or eliminated tumor giant cells in patients with giant-cell tumor of the bone and also increased new bone formation, according to the results of a phase II study published in Clinical Cancer Research. Giant cell tumor of bone (GCTB) is a rare, aggressive, benign osteolytic tumor in which bone destruction is […]

View full entry

Tags: Bone Cancer, General Bone Cancer, News


March 26th, 2012

Aspirin Continues to Look Promising for Cancer Prevention

By

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce the risk of several types of cancer, with particularly strong evidence […]

View full entry

Tags: Anal Cancer, Bladder Cancer, Bone Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Gastric Cancer, General Bone Cancer, General Brain Cancer, General Head and Neck Cancer


September 27th, 2011

Xgeva Delays Onset of Bone Metastases

By

Among men with prostate cancer that has stopped responding to hormonal therapy, the bone drug Xgeva™ (denosumab) delayed the spread of cancer to the bones. These results were presented at the 2011 European Multidisciplinary Cancer Conference. Androgen deprivation therapy (ADT) often plays an important role in the treatment of prostate cancer. ADT slows or stops […]

View full entry

Tags: Bone Cancer, Early Stage I-II (A-B) Prostate Cancer, General Bone Cancer, Locally Advanced Stage III (C) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer


July 15th, 2011

Stay on Top of Your Family History of Cancer

By

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s important to update this information periodically with your healthcare provider. This was the conclusion of a study published in […]

View full entry

Tags: All Cancer Types, Anal Cancer, Bladder Cancer, Bone Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Gastric Cancer, Gastrointestinal Stromal Tumors, General Bone Cancer


February 11th, 2010

Denosumab Active Against Giant Cell Tumor of Bone

By

In a Phase II clinical trial, denosumab produced high rates of tumor response among patients with recurrent or unresectable giant cell tumors of bone. These results were published in Lancet Oncology. Denosumab is an investigational drug that targets a protein known as the RANK ligand. This protein regulates the activity of osteoclasts (cells that break […]

View full entry

Tags: Bone Cancer, General Bone Cancer, News